Yesterday afternoon I attended the opening of the European headquarters of Quintiles, one of the world’s largest clinical research organisations, in Reading, UK.
It is great to see Quintiles making the most of the UK’s strong science heritage, world-class scientists and leading academics. Their new UK-based headquarters was opened by Chairman and CEO Dennis Gillings, CBE, with a supportive quote read out from Parliamentary Under-Secretary of State for Health Lord Howe.
The new facility highlights Quintiles' recognition of the importance of Europe – and especially the UK – to the life sciences. The location of their new headquarters is a clear statement of belief in the UK’s ability to deliver in this area.
This is a huge investment in the UK by a leading biopharmaceutical company – their investment presents us with the opportunity to dispel some of the myths and incorrect perceptions about the UK research environment.
Quintiles has shown that they believe the UK is able to deliver on clinical trials throughout Europe from Phase I through to launch. This is a significant statement which recognises the important work of the National Institute for Health Research and others to ensure that the UK is seen as a leader in research and development (R&D). We have made significant progress working together, and the Government’s ‘Plan for Growth’ announced earlier this year recognised the valuable contribution to be made by R&D into the health and wealth agenda.
We hope this investment by Quintiles will persuade other decision-makers in the pharmaceutical industry to follow suit and direct more clinical research in UK and Europe. The UK is most certainly open for business.
Dr Allison Jeynes-Ellis ABPI Medical and Innovation Director